Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Blood

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Blood|July 21, 2017
Targeting BCL-2 in B-cell lymphomasMatthew S Davids
Blood|July 29, 2025
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitorMazyar Shadman, Matthew S Davids
Blood|July 18, 2018
The rise of apoptosis: targeting apoptosis in hematologic malignanciesRebecca Valentin, Stephanie Grabow, Matthew S Davids
Blood|January 24, 2018
Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantationRobert J Soiffer, Matthew S Davids, Yi-Bin Chen
Blood|September 8, 2012
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemiaMatthew S Davids, Jing Deng, Adrian Wiestner, et al.
Blood|August 3, 2016
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisGabriela Pavlasova, Marek Borsky, Vaclav Seda, et al.
Blood|January 7, 2018
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutre, Michael Choi, Richard R Furman, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
Blood|October 5, 2016
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S Ujjani, Sin-Ho Jung, Brandelyn Pitcher, et al.
Blood|September 30, 2025
Mechanisms of immune escape and extramedullary tropism in leukemia cutisLivius Penter, Katie Maurer, Nicoletta Cieri, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Blood|July 21, 2017
Targeting BCL-2 in B-cell lymphomasMatthew S Davids
Blood|July 29, 2025
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitorMazyar Shadman, Matthew S Davids
Blood|July 18, 2018
The rise of apoptosis: targeting apoptosis in hematologic malignanciesRebecca Valentin, Stephanie Grabow, Matthew S Davids
Blood|January 24, 2018
Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantationRobert J Soiffer, Matthew S Davids, Yi-Bin Chen
Blood|September 8, 2012
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemiaMatthew S Davids, Jing Deng, Adrian Wiestner, et al.
Blood|August 3, 2016
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisGabriela Pavlasova, Marek Borsky, Vaclav Seda, et al.
Blood|January 7, 2018
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutre, Michael Choi, Richard R Furman, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
Blood|October 5, 2016
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S Ujjani, Sin-Ho Jung, Brandelyn Pitcher, et al.
Blood|September 30, 2025
Mechanisms of immune escape and extramedullary tropism in leukemia cutisLivius Penter, Katie Maurer, Nicoletta Cieri, et al.
Pageof 3